Chunfeng He

Feb 22, 2024 | biorxiv.org | Chunfeng He |Yue Xu |Yuan Zhou |Jiayao Fan

AbstractGenetics-informed drug repositioning presents a streamlined and cost-efficient way to broaden therapeutic options. However, leveraging the full spectrum of molecular signatures remains underexplored. We introduce TReD (Transcriptome-informed Reversal Distance), integrating population-level disease signatures robust to reverse causality and cell-based drug-induced response profiles.

Oct 26, 2023 | biorxiv.org | Chunfeng He |Yue Xu |Yuan Zhou |Jiayao Fan

AbstractDrug repositioning presents a streamlined and cost-efficient way to expand the range of therapeutic possibilities. Furthermore, drugs with genetic evidence are more likely to progress successfully through clinical trials towards FDA approval. Exploiting these developments, single gene-based drug repositioning methods have been implemented, but approaches leveraging the entire spectrum of molecular signatures are critically underexplored.